Lymphoma
Conditions
Keywords
Follicular Lymphoma, Zevalin, Ibritumomab Tiuxetan, IDEC-Y2B8, Fludarabine, Fludara, Dexamethasone, Mitoxantrone, Rituximab, Rituxan, R-FND, Fludarabine Phosphate, Decadron
Brief summary
The goal of this clinical research study is to learn if chemotherapy given with rituximab, followed by Ibritumomab tiuxetan (Zevalin), and then followed by rituximab can help to control lymphoma. The safety of this treatment schedule will also be studied. Objectives: 1. To assess whether the time to progression for these high-risk patients can be prolonged to a median of 36 months, compared to the historical expectation of approximately 24 months. 2. To assess the tolerance and efficacy of Y2B8 (Zevalin) after R-FND (rituximab, fludarabine, mitoxantrone, dexamethasone) in patients with high-risk stage III-IV follicular lymphoma 3. To assess overall response, failure-free survival, and survival of this strategy compared to our historical experience with FND (fludarabine, mitoxantrone, dexamethasone) alone or R-FND 4. To assess the tolerance and efficacy of maintenance therapy with rituximab. 5. To maximize the 12-month molecular remission rate for patients with high-risk stage III-IV follicular lymphoma 6. to correlate the results of quantitative PCR assay with classical PCR and with clinical outcome
Detailed description
The treatments used in this program include several standard chemotherapy agents (fludarabine, mitoxantrone, and dexamethasone). Also, immune therapy agents will be given, including rituximab (a monoclonal antibody that attacks B-cells, which is what this type of lymphoma is made of), and Ibritumomab tiuxetan (another similar monoclonal antibody, which delivers radiation to the lymphoma cells to strengthen the attack). You will receive rituximab on Days 1 and 8 of the first cycle, and on Day 1 only of Cycles 2-4 of the monthly cycles of chemotherapy, called R-FND. R-FND includes rituximab and fludarabine, mitoxantrone, and dexamethasone. Fludarabine will be given for 3 days, mitoxantrone for 1 day, and dexamethasone for 5 days of each 28-day cycle (FND). After 4 cycles of R-FND, you will receive Ibritumomab tiuxetan. After the Ibritumomab tiuxetan, you will receive rituximab every 2 months for 1 year. All are given by vein. Sometimes dexamethasone can be given in pill form. During the study, you will have blood tests (about 2 tablespoons), sometimes every week. Every 2 cycles, you will have a chest x-ray and CT scans of the abdomen and pelvis. Bone marrow samples will be taken. Heart function tests will be done as needed. If you desire, it may be possible for you to receive some of your study treatment at home (from your home doctor). Your study doctor will discuss this possibility with you. If this is the case, your home doctor will receive a letter telling him about this study and asking him if he wishes to participate in your treatments. He will be asked to provide the study doctors at M. D. Anderson specific information about your treatments and any side effects you may have. All communications between your home doctor and your study doctors will be included as part of your M. D. Anderson medical record. After the study ends, you will return for checkups every 3 months in the first year, every 4 months in Years 2 and 3, and every 6 months in Years 4 and 5. After that, checkups will be needed once a year. Blood (about 2 tablespoons) and bone marrow samples will be taken at these visits. This is an investigational study. Ibritumomab tiuxetan and rituximab are approved by the FDA for commercial use. The other drugs used in the study are also approved for commercial use by the FDA. About 50 patients will take part in the study. All will be enrolled at M. D. Anderson.
Interventions
DRUGFludarabine
25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
DRUGMitoxantrone
10 mg/m\^2 IV over 5-30 minutes on Day 2.
DRUGRituximab
375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
DRUGZevalin
0.3 mCi/kg IV after 4 cycles of R-FND.
DRUGDexamethasone
20 mg by mouth (PO) or IV daily on Days 2-6.
Sponsors
Genentech, Inc.
Biogen
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with high-risk Ann Arbor stage III-IV follicular lymphoma. High-risk is defined by advanced stage (III or IV), plus any 2 of the following features: age 60 or greater; elevated LDH; Hgb \< 12; or number of involved nodal sites 5 or more . 2. Patients will be previously untreated. 3. Adequate organ function. 4. Follicular lymphoma, grade 3 (follicular large cell lymphoma): If eligible for a current large cell lymphoma protocol, that alternative protocol is recommended, particularly grade 3b or FLCL patients characterized as large non-cleaved cell. However, both FND and rituximab have established efficacy in FLCL, so if a patient is not eligible for a protocol for aggressive lymphoma (e.g., because of SCCL in the marrow), then registration on this trial is permitted. 5. Biopsy or fine-needle aspiration (FNA) material is strongly recommended for bcl-2 studies to verify rearrangement status of all patients who are designated germline. (see section 6.4). For other patients, tissue availability is desirable but not mandatory. 6. Patients must have a performance status of Zubrod 3 or better 7. Patients must have adequate renal and hepatic function (creatinine \< 2mg%; bilirubin \< 2 mg%). Patients with renal or liver dysfunction due to organ infiltration by lymphoma may be eligible after discussion with the study chairman. 8. Patients may not receive other concurrent chemotherapy, radiotherapy, or immunotherapy. 9. Patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital.
Exclusion criteria
1. Patients who are unable or unlikely to be able to adhere to the treatment plan or to return to Houston for follow-up visits because of geographical, economic, emotional, or social considerations are not eligible for this study. Note: some follow-up care may be provided by outside physicians as long as the MD Anderson Cancer Center (MDACC) protocol for outside physician participation is strictly adhered to. 2. Patients with an absolute peripheral granulocyte count of \< 1,000 and platelet count \< 100,000 unless due to marrow infiltration or hypersplenism. 3. Patients with organ dysfunction, including bilirubin of \> 2 mg% or serum creatinine level \> 2 mg%, unless the alteration is due to lymphoma. 4. Patients with HIV infection should not be registered on this protocol. 5. Patients with an antecedent malignancy whose prognosis is poor (\< 90% probability of surviving for 5 yrs). 6. All patients should have a cardiac ejection fraction of 50% or more by echocardiography or multiple gated acquisition scan (MUGA). 7. Patients who will not accept transfusions of blood products or supportive care measures such as antibiotics are not eligible for this study. 8. Female patients must not be pregnant or lactating, and men and women of reproductive potential must follow accepted birth control methods. 9. Patients who have received prior murine antibody therapy will be excluded. 10. Patients with evidence of active or prior infection of Hepatitis B are excluded. (Note: Persons vaccinated for Hepatitis B who have + antibodies are not excluded).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Time to Progression (TTP) | baseline, 2 and 4 courses, approximately month 8, 9, and 12 months, then restaging every 4 months, then at 2 years every 4-6 months, then yearly until progressive disease or lost to follow up, average of 10 years | Regimen regarded as a success if median TTP can be prolonged to 36 months or greater. Time to Progression measured by the method of Kaplan and Meier, and accompanied by 95% confidence interval. Complete Response (CR) defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays and Partial Response (PR) is defined as a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. av |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerance and Efficacy of Maintenance Therapy With Rituximab | cycle 1 and every 2 weeks thereafter until completion of therapy, an average of 10 years | To assess the tolerance and efficacy of maintenance therapy with rituximab. Participants proceeded to the rituximab maintenance program of 6 treatments comprising 1 every 2 months. CR: defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays. CRu: defined as CR unconfirmed on the basis of minimal residual abnormalities on x-ray such as a residual mass \<25% of original measurement, and or residual indeterminate bone marrow aggregates. PR: a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. Progressive disease (PD) is also defined by the appearance of new lymph nodes, of other new or worsening sites of disease, such as \> 50% increase in the size of liver and/or spleen, or a \> 50% increase in absolute number of circulating lymphocytes. |
| Median Progression Free Survival | up to 5 years | Progression-free survival time is defined as time from registration/randomization to the date of progression or death from any cause. Median Progression Free Survival estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval. |
| Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT) | cycle 1 and every 2 weeks thereafter until completion of therapy, an average of 10 years | To assess the tolerance and efficacy of maintenance therapy with YIT. CR: defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays. CRu: defined as CR unconfirmed on the basis of minimal residual abnormalities on x-ray such as a residual mass \<25% of original measurement, and or residual indeterminate bone marrow aggregates. PR: a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. Progressive disease (PD) is also defined by the appearance of new lymph nodes, of other new or worsening sites of disease, such as \> 50% increase in the size of liver and/or spleen, or a \> 50% increase in absolute number of circulating lymphocytes. |
| Overall Survival | up to 5 years | OS is defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact. Median Overall Survival was estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval. |
| Percentage of Participants With Overall Survival Rate at 10 Years | 10 years | OS is defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact. Overall Survival Rate estimated by the method of Kaplan and Meier. |
| Progression Free Survival at 10 Years | 10 years | Progression-free survival time is defined as time from registration/randomization to the date of progression or death from any cause. PFS was estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval. |
Countries
United States
Participant flow
Recruitment details
Recruitment period from June 2004 to May 2009.
Pre-assignment details
Forty-nine patients with Follicular Lymphoma were enrolled in this single site, phase II trial. Two patients were removed after registration and did not start treatment: the first, due to physician's decision; the second, to pursue treatment at home.
Participants by arm
| Arm | Count |
|---|---|
| R-FIND + Zevalin Fludarabine 25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m\^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6. | 49 |
| Total | 49 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | Death | 1 |
| Overall Study | Physician Decision | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | R-FIND + Zevalin |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 20 Participants |
| Age, Categorical Between 18 and 65 years | 29 Participants |
| Age, Continuous | 62 years |
| Ann Arbor Stages Ann Arbor Stage III | 7 Participants |
| Ann Arbor Stages Ann Arbor Stage IV | 42 Participants |
| Beta 2 Microglobulin (B2M) B2M, mg/l>/= 2.2 | 33 Participants |
| Beta 2 Microglobulin (B2M) B2M, mg/l <2.2 | 15 Participants |
| Bone Marrow Biopsy Bone Marrow Biopsy - Neg | 11 Participants |
| Bone Marrow Biopsy Bone Marrow Biopsy - Pos | 37 Participants |
| Bulky Disease Bulky Disease >/=5 cm | 24 Participants |
| Bulky Disease No bulky disease | 25 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 23 Participants |
| Follicular Lymphoma International Prognostic Index (FLIPI) FLIPI Score 3 | 40 Participants |
| Follicular Lymphoma International Prognostic Index (FLIPI) FLIPI Score 4 | 6 Participants |
| Follicular Lymphoma International Prognostic Index (FLIPI) FLIPI Score 5 | 2 Participants |
| Lactate Dehydrogenase (LDH) LDH, units/ </= 618 | 35 Participants |
| Lactate Dehydrogenase (LDH) LDH, units/ >618 | 14 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 43 Participants |
| Region of Enrollment United States | 49 participants |
| Sex: Female, Male Female | 25 Participants |
| Sex: Female, Male Male | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 8 / 49 |
| other Total, other adverse events | 46 / 49 |
| serious Total, serious adverse events | 34 / 49 |
Outcome results
Primary
Number of Participants With Time to Progression (TTP)
Regimen regarded as a success if median TTP can be prolonged to 36 months or greater. Time to Progression measured by the method of Kaplan and Meier, and accompanied by 95% confidence interval. Complete Response (CR) defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays and Partial Response (PR) is defined as a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. av
Time frame: baseline, 2 and 4 courses, approximately month 8, 9, and 12 months, then restaging every 4 months, then at 2 years every 4-6 months, then yearly until progressive disease or lost to follow up, average of 10 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| R-FIND + Zevalin | Number of Participants With Time to Progression (TTP) | Partial Response (PR) | 4 Participants |
| R-FIND + Zevalin | Number of Participants With Time to Progression (TTP) | Complete Response (CR) | 42 Participants |
Secondary
Median Progression Free Survival
Progression-free survival time is defined as time from registration/randomization to the date of progression or death from any cause. Median Progression Free Survival estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval.
Time frame: up to 5 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| R-FIND + Zevalin | Median Progression Free Survival | 84 months |
Secondary
Overall Survival
OS is defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact. Median Overall Survival was estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval.
Time frame: up to 5 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| R-FIND + Zevalin | Overall Survival | 143 months |
Secondary
Percentage of Participants With Overall Survival Rate at 10 Years
OS is defined as the interval from first dose of study treatment to the date of death, irrespective of the cause of death; subjects still alive will be censored at the date of the last contact. Overall Survival Rate estimated by the method of Kaplan and Meier.
Time frame: 10 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| R-FIND + Zevalin | Percentage of Participants With Overall Survival Rate at 10 Years | 69 percentage of participants |
Secondary
Progression Free Survival at 10 Years
Progression-free survival time is defined as time from registration/randomization to the date of progression or death from any cause. PFS was estimated by the method of Kaplan and Meier, and accompanied by 95% confidence interval.
Time frame: 10 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| R-FIND + Zevalin | Progression Free Survival at 10 Years | 49 months |
Secondary
Tolerance and Efficacy of Maintenance Therapy With Rituximab
To assess the tolerance and efficacy of maintenance therapy with rituximab. Participants proceeded to the rituximab maintenance program of 6 treatments comprising 1 every 2 months. CR: defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays. CRu: defined as CR unconfirmed on the basis of minimal residual abnormalities on x-ray such as a residual mass \<25% of original measurement, and or residual indeterminate bone marrow aggregates. PR: a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. Progressive disease (PD) is also defined by the appearance of new lymph nodes, of other new or worsening sites of disease, such as \> 50% increase in the size of liver and/or spleen, or a \> 50% increase in absolute number of circulating lymphocytes.
Time frame: cycle 1 and every 2 weeks thereafter until completion of therapy, an average of 10 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| R-FIND + Zevalin | Tolerance and Efficacy of Maintenance Therapy With Rituximab | Complete Response (CR) | 38 Participants |
| R-FIND + Zevalin | Tolerance and Efficacy of Maintenance Therapy With Rituximab | Progression Disease (PD) | 3 Participants |
Secondary
Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT)
To assess the tolerance and efficacy of maintenance therapy with YIT. CR: defined as those who achieve a normal state which includes no detectable evidence of disease on x-rays. CRu: defined as CR unconfirmed on the basis of minimal residual abnormalities on x-ray such as a residual mass \<25% of original measurement, and or residual indeterminate bone marrow aggregates. PR: a 50% or more reduction in the sum of the products of the diameters of the 6 largest measurable lesions. No new sites of disease. Progressive disease (PD) is also defined by the appearance of new lymph nodes, of other new or worsening sites of disease, such as \> 50% increase in the size of liver and/or spleen, or a \> 50% increase in absolute number of circulating lymphocytes.
Time frame: cycle 1 and every 2 weeks thereafter until completion of therapy, an average of 10 years
Population: Participants that received YIT treatment.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| R-FIND + Zevalin | Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT) | Complete Response (CR) | 37 Participants |
| R-FIND + Zevalin | Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT) | Progressive Disease | 1 Participants |